Is generic tirzepatide available in the United States?

No. FDA has accepted proposed generic tirzepatide applications from Sandoz and other companies for review, but acceptance is not approval. As of September 18, 2026, the day this article was written, FDA's Orange Book showed no approved tirzepatide ANDA, so no U.S. pharmacy could dispense a generic version of Mounjaro or Zepbound.

Is tirzepatide the generic name for Mounjaro and Zepbound?

Yes. Tirzepatide is the established, nonproprietary name of the active medicine; Mounjaro and Zepbound are brand names for products with different labeled uses. That naming fact does not mean a lower-cost generic product is already available. A marketed generic would need its own completed ANDA review and a lawful path through the relevant patents.

When will generic tirzepatide be available?

There is no confirmed U.S. launch date. FDA's August 2026 Orange Book lists a tirzepatide patent through May 13, 2036 and other product, device and use patents into 2039. Review outcomes, patent challenges, settlements, exclusivity and manufacturing readiness can all affect timing, so 2036 is a reference point rather than a promised release year.

Is compounded tirzepatide a generic?

No. A compounded preparation is not a generic. A generic must complete the ANDA route and show required sameness and bioequivalence to a reference medicine. A compounded medication is prepared under a prescription through a different legal framework, and the pending applications from Sandoz or other manufacturers do not transfer their regulatory status to it.

What does FDA acceptance of an ANDA mean?

It means FDA has agreed to review the abbreviated new drug application. It does not mean the proposed medicine passed that review or may be marketed. The applicant still has to meet the generic-drug requirements, and patent or exclusivity barriers may remain even after the scientific work is complete.

Generic Tirzepatide: Under Review, Not Approved

Generic tirzepatide is not available in U.S. pharmacies yet. Tirzepatide is already the generic, or nonproprietary, name for the medicine sold under the brand names Mounjaro and Zepbound. The June 2026 news was that FDA accepted proposed generic applications for review. That means the agency agreed to examine them. It does not mean the products are approved, for sale or about to replace the brands.

What happened with generic tirzepatide

On June 29, 2026, Sandoz announced that FDA had accepted two abbreviated new drug applications, or ANDAs—the application route for a generic medicine. The proposed products are single-dose tirzepatide autoinjectors developed by Sandoz. One application references Mounjaro and the other references Zepbound.

Sandoz's June release said the applications address all indications of those reference medicines. At that time, it described the Mounjaro application as covering type 2 diabetes and the Zepbound application as covering chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. An indication is the condition a product's label says it is used to treat.

Those uses rest on evidence FDA already evaluated for the reference products. In the 40-week SURPASS-2 trial, 1,879 adults with type 2 diabetes were assigned to tirzepatide or semaglutide and researchers measured the change in HbA1c, a marker of average blood sugar (Frías et al., New England Journal of Medicine 2021). In the 72-week SURMOUNT-1 trial of 2,539 adults without diabetes, average weight change ranged from -15.0% to -20.9% across tirzepatide groups, compared with -3.1% with placebo (Jastreboff et al., New England Journal of Medicine 2022).

A generic applicant does not have to rerun those large trials. It has to show that its finished product meets the generic standard.

Acceptance is not approval

This is the part most headlines blur. File acceptance means FDA will review an application. It does not tell us that the proposed product passed review, and it does not grant permission to market it.

FDA explains that an ANDA must show the proposed medicine matches its reference product in the required ways and performs the same way. That includes bioequivalence, meaning the active ingredient reaches the bloodstream at a comparable rate and amount. The proposed autoinjector also brings a device into the review, not just a vial of the molecule (FDA's ANDA overview).

On July 28, 2026, FDA published revised product-specific guidance for generic peptide products, including separate entries for Mounjaro and Zepbound. It covers how applicants should compare the peptide's structure, biological activity and impurities. The guidance is a technical roadmap, not an approval.

There is no public review result or launch date in the Sandoz announcement. Its wording is conditional: the company says the products could be among the first available when a U.S. market forms, subject to approval.

What the filing means right now

As of September 18, 2026, the day this article was written, FDA's August 2026 Orange Book still showed Mounjaro and Zepbound as new drug application entries and no approved tirzepatide ANDA. In plain English, there was still no generic tirzepatide a U.S. pharmacy could dispense.

Sandoz is not alone in preparing for that future market. On July 8, 2026, Amneal and Adalvo announced that FDA had accepted two more tirzepatide autoinjector ANDAs, again referencing Mounjaro and Zepbound. More applications may eventually create price competition, but a filing alone sets neither a price nor an arrival date.

The reference label moved after those filings. In an approval letter signed August 27, 2026, FDA expanded Mounjaro's indication to include reducing the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk. Sandoz's public June release does not say how that later label change will be handled in its pending application.

For someone filling a prescription today, nothing switches automatically. There is no generic substitution at the pharmacy counter and no new Sandoz pen to request.

What the news does not mean

It does not turn compounded tirzepatide into a generic. A compounded preparation is not a generic: a generic must receive its own FDA approval and meet the agency's standards for sameness, manufacturing and bioequivalence. FDA has separately told telehealth companies that calling a compounded drug a generic is misleading (FDA's compounding promotion guidance).

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The compounded tirzepatide guide explains that route in more detail.

The Sandoz filing neither validates nor cancels a compounded prescription. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

The patent clock matters too

Review is only one clock. Patents are another. FDA's August 2026 Orange Book lists U.S. patent 9,474,780 for tirzepatide through May 13, 2036. It also lists device, product and use patents with dates extending into 2039.

That does not make 2036 a promised launch year. A generic applicant can challenge listed patents, reach a settlement or wait for protection to expire. The outcome of those steps—and any resulting exclusivity—can move the date in either direction.

If FDA finishes the scientific review while a legal barrier remains, the application may receive tentative rather than final status. FDA tentative approval means the application is scientifically ready on the information then available but the product still cannot be marketed. It is a milestone, not a pharmacy-shelf date.

What to watch next

The next meaningful document is a review outcome, not another headline about file acceptance. A tentative decision would show the application cleared the scientific review but remained legally blocked. A final decision would clear the regulatory step, though patent litigation, settlements, manufacturing readiness and an announced launch would still matter.

The proposed autoinjector matters as well. A finished generic has to match required features of its reference product; it is not simply bulk tirzepatide placed into any pen. FDA's review covers the product that would actually reach a pharmacy.

Semaglutide offers the closest current precedent: a U.S. application can reach tentative status while the marketed product remains years away. Our generic semaglutide update follows that separate timeline.

Choosing a route before a generic arrives

For now, the real choice is between a branded tirzepatide prescription and, when clinically and legally appropriate, a compounded prescription. It is not between a brand and a marketed generic, because that generic does not yet exist in the United States.

At Promise, a licensed provider reviews every request and not everyone qualifies. The provider decides whether a compounded prescription is appropriate for the individual in front of them; a pending Sandoz application does not make that decision.